Literature DB >> 12535224

Immune parameters relevant to neural xenograft survival in the primate brain.

F Cicchetti1, W Fodor, T W Deacon, C van Horne, S Rollins, W Burton, L C Costantini, O Isacson.   

Abstract

The lack of supply and access to human tissue has prompted the development of xenotransplantation as a potential clinical modality for neural cell transplantation. The goal of the present study was to achieve a better understanding of the immune factors involved in neural xenograft rejection in primates. Initially, we quantified complement mediated cell lysis of porcine fetal neurons by primate serum and demonstrated that anti-C5 antibody treatment inhibited cell death. We then developed an immunosuppression protocol that included in vivo anti-C5 monoclonal antibody treatment, triple drug therapy (cyclosporine, methylprednisolone, azathioprine) and donor tissue derived from CD59 or H-transferase transgenic pigs and applied it to pig-to-primate neural cell transplant models. Pre-formed alphaGal, induced alphaGal and primate anti-mouse antibody (PAMA) titers were monitored to assess the immune response. Four primates were transplanted. The three CD59 neural cell recipients showed an induced anti-alphaGal response, whereas the H-transferase neural cell recipient exhibited consistently low anti-alphaGal titers. Two of these recipients contained surviving grafts as detected by immunohistochemistry using selected neural markers. Graft survival correlated with high dose cyclosporine treatment, complete complement blockade and the absence of an induced PAMA response to the murine anti-C5 monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535224     DOI: 10.1034/j.1399-3089.2003.01130.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  6 in total

Review 1.  Immune problems in central nervous system cell therapy.

Authors:  Roger A Barker; Håkan Widner
Journal:  NeuroRx       Date:  2004-10

Review 2.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

3.  Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation.

Authors:  Caroline Martin; Martine Plat; Véronique Nerriére-Daguin; Flora Coulon; Svetlana Uzbekova; Eric Venturi; Françoise Condé; Jean-Michel Hermel; Philippe Hantraye; Laurent Tesson; Ignacio Anegon; Benoit Melchior; Marc Peschanski; Brigitte Le Mauff; Françoise Boeffard; Solène Sergent-Tanguy; Isabelle Neveu; Philippe Naveilhan; Jean-Paul Soulillou; Michel Terqui; Philippe Brachet; Bernard Vanhove
Journal:  Transgenic Res       Date:  2005-08       Impact factor: 2.788

4.  Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.

Authors:  Maria Sundberg; Helle Bogetofte; Tristan Lawson; Johan Jansson; Gaynor Smith; Arnar Astradsson; Michele Moore; Teresia Osborn; Oliver Cooper; Roger Spealman; Penelope Hallett; Ole Isacson
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

5.  Remyelination of the nonhuman primate spinal cord by transplantation of H-transferase transgenic adult pig olfactory ensheathing cells.

Authors:  Christine Radtke; Yukinori Akiyama; Jane Brokaw; Karen L Lankford; Konstantin Wewetzer; William L Fodor; Jeffery D Kocsis
Journal:  FASEB J       Date:  2003-12-04       Impact factor: 5.191

6.  Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.

Authors:  Wioleta M Zelek; Georgina E Menzies; Andrea Brancale; Brigitta Stockinger; Bryan Paul Morgan
Journal:  Immunology       Date:  2020-07-13       Impact factor: 7.215

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.